NYSE$AGL
agilon health inc. · Q1 2021 earnings
Q1 2021 earnings · · Investor relations
Briefing
agilon health reported first quarter results, demonstrating revenue and membership growth.
agilon health's first quarter results showed a 42% increase in total revenue to $413 million and a 35% increase in membership. Including a retroactive group MA contract, revenue growth would have been approximately 50% and membership growth would have been 42%. The company reported a net loss from continuing operations of $14 million and an Adjusted EBITDA of $4 million.
- Total revenue increased 42% year-over-year to $413 million.
- Membership increased 35% year-over-year to approximately 165,300.
- Same geography membership growth increased 8% from 2020 and same geography membership growth of 15% including the retroactive group contract
- Net loss from continuing operations was $14 million, compared to $8 million in 2020.
Headline financials
Revenue & EPS history
agilon health · Revenue · Quarterly
$413M
Revenue by segment
agilon health · $413M total across 2 segments · Q1 2021
- Medical Services Revenue$412M+42.3%99.8%
- Other Operating Revenue$692K-43.9%0.2%
Forward guidance
agilon health provided guidance for the second quarter and full fiscal year 2021, including estimates for ending members, total revenues, and Adjusted EBITDA.
Tailwinds
- Second quarter 2021 total revenue is expected to be between $470 million and $475 million.
- Full year 2021 total revenue is expected to be between $1.765 billion and $1.780 billion.
- Second quarter 2021 ending members are expected to be between 175,000 and 177,000.
- Full year 2021 ending members are expected to be between 182,000 and 184,000.
- Total revenue outlook for the second quarter 2021 includes an estimated $24 million associated with the group MA contract attributable to the first quarter.
Headwinds
- Second quarter 2021 Adjusted EBITDA is expected to be between $(41) million and $(38) million.
- Adjusted EBITDA loss reflected in the full year 2021 outlook is expected to be weighted to the back half of the fiscal year.
- The company has not reconciled guidance for Adjusted EBITDA to net income (loss).
- The company has not provided forward-looking guidance for net income (loss).
- The uncertainty around certain items that may impact net income (loss), including stock-based compensation, that are not within our control or cannot be reasonably predicted.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports
-2.6%
Avg return
Earnings day
-0.0%
Avg return
5 days after
+6.7%
Avg return
30 days after
50%
10 / 20 earnings
Positive
+20.2%
Q4 2025
Best reaction
-36.1%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.2% | +122.0% | +256.9% | |
| Q4 2025 | +20.2% | +13.4% | -20.8% | |
| Q3 2025 | +5.1% | -9.0% | -9.9% | |
| Q1 2025 | -25.6% | -33.4% | -51.6% | |
| Q4 2024 | -7.4% | -17.9% | +23.7% | |
| Q3 2024 | -36.1% | -35.1% | -24.7% | |
| Q2 2024 | -12.7% | -14.6% | -36.8% | |
| Q1 2024 | +7.5% | +7.5% | +40.8% | |
| Q4 2023 | +3.1% | -2.1% | -1.1% | |
| Q3 2023 | -13.1% | -19.0% | -33.1% | |
| Q2 2023 | +0.7% | +3.7% | -7.9% | |
| Q1 2023 | -3.4% | -6.6% | -18.9% | |
| Q4 2022 | +15.4% | +14.8% | +12.0% | |
| Q3 2022 | -12.7% | -7.9% | -8.6% | |
| Q2 2022 | -3.3% | -0.4% | -20.3% | |
| Q1 2022 | -8.6% | -19.4% | +1.3% | |
| Q4 2021 | +10.6% | +2.4% | +31.7% | |
| Q3 2021 | +2.7% | +3.6% | -9.5% | |
| Q2 2021 | -3.8% | -6.3% | -3.4% | |
| Q1 2021 | +6.3% | +4.0% | +14.0% | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro